51st week of 2021 patent applcation highlights part 8 |
Patent application number | Title | Published |
20210393509 | AGENT FOR MITIGATING HOT FLASH, COSMETIC PRODUCT, AND METHOD OF USING COSMETIC PRODUCT - Disclosed is a hot flash-mitigating agent that is highly effective in mitigating hot flashes associated with premenstrual syndrome. The hot flash-mitigating agent contains mallow extract as an active ingredient. | 2021-12-23 |
20210393510 | PROBIOTIC SKIN FORMULATIONS - Described herein are dermatological compositions, formulations containing wild type or genetically modified | 2021-12-23 |
20210393511 | OTIC GEL FORMULATIONS FOR TREATING OTITIS EXTERNA - Disclosed herein are methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2021-12-23 |
20210393512 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE - The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, gastric motility, and volume and viscosity of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects. | 2021-12-23 |
20210393513 | CHEMICALLY MODIFIED SMALL MOLECULES - Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material. | 2021-12-23 |
20210393514 | DOCETAXEL COMPOSITION FOR INJECTION AND PREPARATION METHOD THEREFOR - A docetaxel composition for injection and a preparation method therefor. The composition comprises the following components in parts by weight: 1 part of docetaxel, 20-60 parts of cyclodextrin, 5-80 parts of a solubilizer, 10-20 parts of stabilizer 1, 0.2-30 parts of stabilizer 2, and 0.001-1.0 part of an additive. The composition does not comprise ethanol and polysorbate, and ethanol is not used in the preparation process thereof. | 2021-12-23 |
20210393515 | Perineural Administration of Resiniferatoxin for Treatment of Maladaptive Pain - Disclosed herein are methods of administering resiniferatoxin (RTX) perineurally for treatment of maladaptive pain, and compositions for use in such methods. | 2021-12-23 |
20210393516 | Solid Implant Formulation for Drug Delivery - A biodegradable delivery device is disclosed that is implanted into patients to provide an extended release of one or more active pharmaceuticals for a therapeutic purpose. The delivery device comprises of: 1) an outer sheath that is composed of an inert biodegradable material that prevents the direct interactions of the core(s) with patient tissues and also facilitates the homogenous access of solvent to the surface area of the core to enable predictable core ingredient dissolution, depletion and safe and effective concentrations. 2) A Primary Core comprising one or more active ingredients plus excipients, including markers, that biodegrades and elutes all its ingredients before the sheath degrades. 3) A Secondary Core at the geometric center of the Primary core comprising a marker (including an active pharmacological or inactive ingredient that can be detected by bioanalysis, or a radio-opaque marker) that can signal when the secondary core is exposed, and excipients, which biodegrades and elutes its ingredients. 4) All elements have a marker excipient that renders the device observable remotely, including by x-ray detecting barium sulfate. The Secondary Core has a marker signal that can be distinguished from the Primary Core and Outer sheath. | 2021-12-23 |
20210393517 | BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS - A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein. | 2021-12-23 |
20210393518 | NASAL HYGIENE METHOD AND COMPOSITION - A composition for and method of practicing nasal hygiene to wash and moisturize the nasal passage. Where the nasal wash comprises a liquid homogenized compound of water, chlorine dioxide (or source thereof), olfactory stimulants, unsaturated fatty acids, and fixing agents. Where the unsaturated fatty acid component comprises from 0.01% to 1% by weight of the compound. | 2021-12-23 |
20210393519 | CANNABINOID SYRUP AND METHODS FOR MAKING AND USING SAME - Provided are water-soluble and/or alcohol-soluble cannabinoid syrups recovered from a dispersion comprising a sugar, sugar alcohol, or sugar substitute; water (e.g., fruit or plant water); and a cannabinoid, the dispersion comprising less than about 10% by weight of alcohol. Also provided are products comprising the cannabinoid syrup prepared by the disclosed method, including a variety of comestible products. | 2021-12-23 |
20210393520 | TREATMENT OF GRAM-NEGATIVE FOLLICULITIS OR AN INFLAMMATION THEREOF WITH BESIFLOXACIN - This disclosure is directed to a method of treating a patient suffering from gram-negative folliculitis or an inflammation thereof by applying a topical formulation of besifloxacin hydrochloride to the affected skin area and its surrounding. | 2021-12-23 |
20210393522 | COMPOSITIONS FOR SOLUBILIZING WATER-INSOLUBLE ACTIVE INGREDIENTS - The present invention provides compositions for solubilizing water-insoluble and poorly water-soluble or poorly permeable active ingredients such as drugs, nutritional supplements, and essential oils. The compositions are useful for administration of the active ingredient to the subject via various routes and provide good bioavailability of the active. The compositions are generally clear and non-turbid and are useful, for example, for preparing formulations of cannabinoid compounds. | 2021-12-23 |
20210393523 | AROMATIC RING SUBSTITUTED AMPHIPHILIC POLYMERS AS DRUG DELIVERY SYSTEMS - An amphiphilic block copolymer having any one of the formulas S-[B]-H, S-[B]-H(D), D-[B]-H, S-B(D)-H, S-[B]-H-[B]-S, S-[B]-H(D)-[B]-S, D-[B]-H-[B]-S, D-[B]-H-[B]-D, S-B(D)-H-[B]-S or S-B(D)-H-B(D)-S; wherein S is a hydrophilic surface stabilizing group; B is a spacer group; H is a hydrophobic polymer or oligomer; D is a drug molecule; ( ) denotes that the group is bonded directly or indirectly as a side chain or as part of a side chain group to the adjacent group; [ ] denotes that the group is optional; and - denotes that each of the adjacent S, B, H or D are linked directly to one another or indirectly to one another via a linker group. | 2021-12-23 |
20210393524 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOMODULATING AGENT AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising at least one liposome and a therapeutic agent for treating an auto-immune disease with a high therapeutic agent to lipid ratio and a high encapsulation efficiency. The pharmaceutical composition improves the pharmacokinetic profile and sustains the release of the therapeutic agent. Also provided is the method for treating an auto-immune disease using the pharmaceutical composition disclosed herein. | 2021-12-23 |
20210393525 | LIPOSOMAL COMPOSITION CONTAINING MILD ACIDIC ACTIVE AGENT - Provided is a method for preparing a liposomal composition. The method comprises the step of contacting a liposome solution with a mild acidic agent for a limited time. The liposome solution comprises a weak acid salt encapsulated within an aqueous interior space separated from the aqueous medium by a membrane comprised of a lipid mixture containing one or more lipids and a hydrophilic polymer conjugated lipid at a molar percentage of less than 3% based on the total amount of the lipid mixture. The time for encapsulating the agent to a desired amount at a predetermined ratio to lipids is dramatically reduced even under a condition without elevating the temperature to above ambient environment. | 2021-12-23 |
20210393526 | ENCHOLEATED ANTIFUNGAL COMPOUNDS FOR CENTRAL NERVOUS SYSTEM DELIVERY AND TREATMENT OF CRYPTOCOCCUS INFECTIONS - The present application is directed to a cochleate composition including one or more cochleates and at least two anti-fungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, oposaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed. | 2021-12-23 |
20210393527 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF - The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome. | 2021-12-23 |
20210393528 | Water Soluble Silicon-Containing Granulate - A water-soluble silicon-containing granulate comprising a silicon compound of the formula Y | 2021-12-23 |
20210393529 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS - Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions. | 2021-12-23 |
20210393530 | VEGF Antagonist Formulations - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 2021-12-23 |
20210393531 | COMPOSITION OF MULTIVITAMIN FOR STIMULATING GASTROINTESTINAL SYSTEM MOTILITY AND PREPARATION METHOD THEREFOR - The present invention relates to a composition of a multivitamin, vitamins B and C, and a preparation method therefor, and in particular, to a composition of a multivitamin, vitamins B and C for stimulating gastrointestinal system motility and a preparation method therefor. The composition is suitable for preventing and/or treating the statuses or diseases related to a lack of gastrointestinal motility. | 2021-12-23 |
20210393532 | PREPARATION CONTAINING SAXAGLIPTIN AND METHOD FOR PRODUCING THE SAME - A preparation containing saxagliptin having improved stability and a method for producing the same are provided. According to an embodiment of the present invention, a preparation containing saxagliptin including a plain tablet part containing one or more first additive agent selected from a group consisting of D-mannitol, lactose, anhydrous lactose, and anhydrous dibasic calcium phosphate, the plain tablet part containing less than 35% by weight of crystalline cellulose with respect to 100% by weight of the plain tablet part, and a film coating part in contact with the plain tablet part and containing saxagliptin, a salt thereof, or a hydrate thereof, and a method for producing the same are provided. | 2021-12-23 |
20210393533 | METHOD AND SYSTEM FOR FORMING A DOSAGE FORM WITHIN A PACKAGING - A method and system of forming a pharmaceutical dosage form within a portion of a blister packaging. The method includes the steps of providing a blister packaging for the dosage form with depressions. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions. A binding liquid is then deposited in a pattern on the powder layer within the depressions, to bind the particles of the powder layer and form an incremental wetted layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging. | 2021-12-23 |
20210393534 | FILM COATING COMPOSITION AND SOLID PREPARATION - The present invention provides a film coating composition for a solid preparation that is easy to take. The present invention also provides a solid preparation that is easy to take. A film coating composition according to an embodiment of the present invention contains a polyvinyl alcohol-polyethylene glycol graft copolymer and a thickening agent. The thickening agent may be composed of one or more substances that are selected from the group consisting of xanthan gum, locust bean gum, pectin, carrageenan, guar gum, gellan gum, and carboxy vinyl polymer. | 2021-12-23 |
20210393535 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS - The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms. | 2021-12-23 |
20210393536 | METHODS AND COMPOSITIONS RELATED TO EXTRACELLULAR VESICLES - Certain embodiments are directed to methods and compositions related to delivery of therapeutic agents via syncytiotrophoblast-derived extracellular vesicles (EVs). | 2021-12-23 |
20210393537 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS - Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface. | 2021-12-23 |
20210393538 | SILICA-BASED DRUG NANOCAPSULES - Disclosed herein are nanoparticles comprising a therapeutic or diagnostic agent positioned within an orthosilicate inner matrix, and a silica outer shell encapsulating the orthosilicate inner matrix. Also disclosed are methods of treating a disease in a subject comprising administering to the subject a biological carrier cell comprising the nanoparticle. Also disclosed are methods of preparing nanoparticles, methods of delivering nanoparticles comprising a therapeutic or diagnostic agent to a target cell, and methods of loading a therapeutic or diagnostic agent into a biological carrier cell. | 2021-12-23 |
20210393539 | FERRITIN NANOPARTICLES COMPRISING A CHEMOTHERAPEUTIC AGENT - The present invention concerns the field of cancer therapy, and in particular to the use of nanoparticles for the preservation of T cells. In particular, the present invention relates to the use of nanoparticles for the treatment of recurrent cancer and for use as a cancer vaccine. | 2021-12-23 |
20210393540 | NANOPARTICLE-ENCAPSULATED CANNABINOIDS AND METHODS FOR MAKING AND USING SAME - Provided are water-soluble and/or alcohol-soluble cannabinoid nanoparticles recovered from a dispersion comprising a sugar, sugar alcohol, or sugar substitute; water; and a cannabinoid, the dispersion comprising less than about 10% by weight of alcohol. Also provided are products comprising the cannabinoid nanoparticle prepared by the disclosed method, including a variety of comestible products. | 2021-12-23 |
20210393541 | PREPARATION OF NANOPARTICLES USING MODIFIED ICE-TEMPLATE - An improved ice-template method for the production of pure nanodrugs is disclosed, the method including application of a volume of a solution of the drug in 150 uL to a surface area of the ice template of about 200 mm | 2021-12-23 |
20210393542 | DERMAL PATCHES AND GLASS SWABS FOR APPLICATION OF TOPICAL IMMUNOSENSITIZERS - Unit dosage forms, devices, and kits for topical delivery of topical immunosensitizers are provided. These include dermal patches, glass swabs, and kits containing a dermal patch and a glass swab. Among other advantages, the unit dosage forms, devices, and kits presented herein deliver a more consistent and controlled volume of drug solution, prevent underdosing and overdosing, prevent or discourage repeat dosing, and provide a more consistent skin area to which the drug solution is applied. | 2021-12-23 |
20210393543 | COMPOSITION AND DEVICE FOR PREVENTING HYPOGLYCEMIA AND USE THEREOF - A composition for preventing or treating hypoglycemia in a patient in need thereof has a microgel that includes crosslinked polymers containing glucose-responsive moieties; and blood glucose-raising therapeutic agent loaded on or within the microgel. The microgel further includes any one or a combination of a stabilizing component and a loading-assisting component for the blood glucose- raising therapeutic agent. The polymers containing the glucose-responsive moieties form secondary crosslinks in response to low glucose level, thereby causing shrinking of the microgel and rapid release of the blood glucose-raising therapeutic agent. The composition can be used to prepare a composite microneedle patch for preventing or treating hypoglycemia, where the composition is embedded or integrated within an array of the microneedles of the microneedle patch device. | 2021-12-23 |
20210393544 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR KETAMINE - Provided herein are transdermal delivery devices comprising ketamine, such as monolithic transdermal patches. Also provided herein are methods of preparing transdermal delivery devices. The transdermal delivery device and monolithic patch herein can have various uses, for example, for treating various diseases or disorders, such as depression, anxiety, and/or pain in a subject in need thereof. | 2021-12-23 |
20210393545 | NATURAL PRODUCT COMPOSITION FOR STIMULATING HAIR GROWTH - The present invention discloses a novel combination of a natural product and minoxidil for the treatment of hair loss and regrowth. In the preferred embodiment, Sandalore® and its analogs are combined with minoxidil and formulated into a solution for the treatment and regrowth of mammalian hair loss. In another embodiment, Sandalore® and its analogs are combined with rosemary oil, emu oil or a combination thereof. | 2021-12-23 |
20210393546 | COMPOSITIONS FOR PREVENTING AND TREATING VIRAL INFECTIONS - Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating viral infections, and methods for treating viral infections by topically or orally administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment. | 2021-12-23 |
20210393547 | USE OF EMODIN IN TREATING RETINAL ISCHEMIA OR A DISEASE, CONDITION, OR DISORDER ASSOCIATED WITH RETINAL ISCHEMIA - A method for treating a subject suffering from retinal ischemia, or a disease, condition, or disorder associated with retinal ischemia, comprising administering to the subject a therapeutically effective amount of emodin or a composition comprising emodin. | 2021-12-23 |
20210393548 | INHIBITORS OF BUNYAVIRIDAE AND USES THEREOF - The present disclosure provides inhibitors of bunyavirus of the formula: | 2021-12-23 |
20210393549 | New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations - This invention disclosed a new use of optically pure R-enantiomer of adrenergic β2 agonists including R-salbutamol, R-terbutaline, R-clenbuterol and R-bambuterol for treatment of inflammatory bowel disease and its extra intestinal manifestations including skin diseases. | 2021-12-23 |
20210393550 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same - Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT | 2021-12-23 |
20210393551 | TAU AGGREGATION INHIBITOR - A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy. | 2021-12-23 |
20210393552 | COMPOSITIONS COMPRISING EPHEDRINE OR AN EPHEDRINE SALT AND METHODS OF MAKING AND USING SAME - The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same. | 2021-12-23 |
20210393553 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PAIN - The present invention relates to pharmaceutical combination for use in the treatment of pain comprising low doses of a beta blocker and an NSAID, pharmaceutical compositions comprising the combination and processes for preparation of the same. The present invention provides a pharmaceutical combination for use in the therapeutic treatment of pain comprising a non-selective NSAID and a low dose of beta blocker. | 2021-12-23 |
20210393554 | NANOEMULSION COMPOSITIONS HAVING ENHANCED PERMEABILITY - The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for topical, mucosal, vaginal, and intranasal applications and allow for the greater delivery of one or more active agents to the application site. | 2021-12-23 |
20210393555 | PETROLATUM-BASED PHMB COMPOSITIONS AND METHODS OF TREATMENT FOR ONYCHOMYCOSIS - Compositions and methods for the treatment of onychomycosis. The compositions include a pharmaceutically effective amount of polyhexamethylene biguanide (PHMB), polyaminopropyl biguanide (PAPB), and/or chlorhexidine (CHG) in a petrolatum carrier. | 2021-12-23 |
20210393556 | TARGETING OCULAR DISEASES WITH NOVEL APE1/REF-1 INHIBITORS - [[(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen-2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein. | 2021-12-23 |
20210393557 | Regulators of the Endoplasmic Reticulum Proteostasis Network - The invention provides compounds for activating the activating transcription factor 6 (ATF6) arm of the unfolded protein response (UPR), or activating the transcriptional targets of ATF6, in the endoplasmic reticulum of a cell, the compounds being of any of formulas (I) through (IX) as described herein. The compounds can be used for treatment of conditions involving gain-of-toxic-function and loss-of-function folding disorders including lysosomal storage diseases, antitrypsin-associated emphysema and similar diseases. These molecules are also expected to have disease-ameliorating effects in Alzheimer's disease and diabetes. | 2021-12-23 |
20210393558 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF PRESSURE ULCERS - The technology subject of the present application aims at providing a methodology for prevention of pressure ulcers. | 2021-12-23 |
20210393559 | Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise - The present invention comprises a composition of β-Hydroxy-β-Methylbutyrate (HMB) with or without Vitamin D to enhance muscle strength and physical functionality, even in individuals not engaged in an exercise training program wherein the enhancements in muscle strength and physical functionality are similar to those seen with exercise. | 2021-12-23 |
20210393560 | ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS - In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. | 2021-12-23 |
20210393561 | Threonate Compounds and Methods of Use Thereof - Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate. | 2021-12-23 |
20210393562 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR NOCTURNAL POLYURIA - There is provided a pharmaceutical composition which includes, as an active ingredient, a combination drug formulation of potassium citrate and sodium citrate hydrate or a sodium bicarbonate formulation. The prevention or treatment of nocturnal polyuria is achieved by administering the pharmaceutical composition. | 2021-12-23 |
20210393563 | METHODS FOR TREATING MICROGLIAL DYSFUNCTION - Among the various aspects of the present disclosure is the provision of methods of treating a microglial dysfunction-associated diseases, disorder, and conditions. The present disclosure provides for a method for treating microglial dysfunction in a subject having a microglial dysfunction-associated neurodegenerative disease comprising administering to a subject a therapeutically effective amount of a microglial rescuing agent. The present disclosure also provides for a method of reversing neuronal damage in a subject having a microglial dysfunction-associated neurodegenerative disease, wherein the microglial dysfunction-associated neurodegenerative disease is characterized by a single nucleotide polymorphisms (SNPs) or mutation in Trem2 or ApoE affecting microglial functions. | 2021-12-23 |
20210393564 | METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS - Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold. | 2021-12-23 |
20210393565 | PREPARATION FOR USE TO INCREASE THE FORMATION OF ONE OR MORE SPECIALIZED PRO-RESOLVING LIPID MEDIATORS (SPM) - The invention relates to preparation comprising at least one omega-3 or omega-6 fatty acid component selected from eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), alpha linolenic acid, stearidonic acid, eicosatetraenoic acid, docosapentaenoic acid, linoleic acid, γ-linolenic acid, or arachidonic acid (ARA) and/or derivatives thereof for use to increase the formation of one or more specialized pro-resolving lipid mediators (SPM) by gastrointestinal microorganisms in the gastrointestinal tract of humans or animals wherein the polyunsaturated fatty acid component comprises an omega-3 or omega-6 fatty acid salt. | 2021-12-23 |
20210393566 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROQUINONE DERIVATIVE FOR PREVENTING OR TREATING OBESITY OR NONALCOHOLIC STEATOHEPATITIS - The present invention relates to a pharmaceutical composition comprising a hydroquinone derivative of general formula 1 as an active ingredient. The pharmaceutical composition has the effects of: enabling the prevention or treatment of obesity by inhibiting weight gain and visceral fat accumulation; and enabling the prevention or treatment of nonalcoholic steatohepatitis by inhibiting fat accumulation in liver tissue and lobular inflammation, and by improving insulin resistance. | 2021-12-23 |
20210393567 | Methods Of Improving The Pharmacokinetics Of Doxepin - Methods of improving the pharmacokinetics of doxepin in a patient. | 2021-12-23 |
20210393568 | DRUG-LOADED NANOFIBER MEMBRANE, METHOD FOR PREPARING THE SAME, AND APPLICATION THEREOF - A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO). | 2021-12-23 |
20210393569 | Taxane Particles and Their Use - Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm | 2021-12-23 |
20210393570 | THERAPEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF NON-MALIGNANT CONDITIONS ASSOCIATED WITH PHOSPHATIDYLINOSITOL-3-KINASE ACTIVATION: OVERGROWTH SPECTRUM, CUTANEOUS CAPILLARY MALFORMATIONS AND SEBORRHEIC KERATOSES - A method of treatment of PIK3CA Related Overgrowth Spectrum, cutaneous capillary malformations, and seborrheic kératoses by administration, to a patient in need, of a pharmaceutical composition including an inhibitor of heat-shock factor 1 (HSF1), wherein the inhibitor of heat-shock factor 1 is selected among one or more of Triptolide, Minnelide, Kribb11, Quercetin, QC-12, Quercetin derivatives, KNK437, Stresgenin B, Emunin, NZ28, Cantharidin, Rocaglamide A, Rohinitib, Rohinitib-Cantharidin hybrids ligands, Arctigenin, and pharmaceutically acceptable derivatives, salts and solvates thereof. | 2021-12-23 |
20210393571 | New Combination Solution for Treating Chemotherapy Refractory Cancer - The use of a pharmaceutical composition in treating cancer in a subject comprising a therapeutically effective amount of a compound of formula (I), a therapeutically effective amount of paclitaxel and a low dose of gemcitabine, and a kit included above composition thereof. | 2021-12-23 |
20210393572 | PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS OF USE FOR TREATING GASTROINTESTINAL CONDITIONS - According to embodiments herein, pharmaceutically active | 2021-12-23 |
20210393573 | TABLETS, FORMULATIONS AND METHODS FOR LOW MELTING POINT ACTIVE INGREDIENTS - A tablet comprises a granulate of an active pharmaceutical ingredient comprising at least one cannabinoid having a melting point less than about 80° C.; sugar, sugar alcohol, or a combination thereof; microcrystalline cellulose having an average particle size less than about 25 μm; silica, silicified microcrystalline cellulose, or a combination thereof; and lubricant comprising sodium stearyl fumarate and lecithin. Methods of forming such a tablet using direct compression of a tablet formulation can be conducted on a large manufacturing scale. | 2021-12-23 |
20210393574 | USE OF CANNABINOID COMPOUND IN NEURODERMATITIS TREATMENT - The present invention discloses use of a cannabinoid compound or pharmaceutically available salts thereof in preparation of a pharmaceutical composition for treatment of neurodermatitis, wherein the cannabinoid compound may be one selected from the group consisting of tetrahydrocannabinol, cannabidiol, cannabidivarin and tetrahydrocannabinovarin, or selected from the group consisting of: (1) a combination of tetrahydrocannabinol and tetrahydrocannabinovarin; (2) a combination of cannabidiol and cannabidivarin; (3) a combination of tetrahydrocannabinol and cannabidivarin; (4) a combination of cannabidiol and tetrahydrocannabinovarin; (5) a combination of cannabidiol, cannabidivarin, and tetrahydrocannabinovarin; (6) a combination of tetrahydrocannabinol, cannabidivarin, and tetrahydrocannabinovarin. | 2021-12-23 |
20210393575 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS - The current disclosure provides use of N-acylated fatty amino acids to reduce absorption variability in cannabinoid-based compositions. | 2021-12-23 |
20210393576 | ORONASAL CBD FORMULATIONS AND USES THEREOF - Provided herein are oronasal formulations including a cannabinoid and N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM). Also provided are methods of using the formulations. | 2021-12-23 |
20210393577 | COMBINATIONS OF CANNABINOIDS AND N-ACYLETHANOLAMINES - The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions. | 2021-12-23 |
20210393578 | BRAIN HEALTH FORMULATION - The invention relates to a unique formulation for brain health. The formulation includes a mixture of CBD, THC, THC-V, and/or flavonoids, along with at least one antioxidant, and preferably an emulsifier, spearmint extract and a film-forming agent. The formulation improves memory and cognition as well as prevents and improves symptoms in dementia and related diseases related to deterioration or loss of memory and/or cognition. | 2021-12-23 |
20210393579 | Anthocyanin and Quercetin Based Formulations for Improved Respiratory Health - A formulation includes anthocyanins and quercetin. The formulation may be implemented in a number of different ways. For example, the formulation includes a sugar phase and an anthocyanin/quercetin phase that includes the anthocyanins and the quercetin. The sugar phase and the anthocyanin/quercetin phase are based on emulsification process(es). The sugar phase is configured to facilitate combination of the anthocyanins and the quercetin including to facilitate distribution of the anthocyanins and the quercetin within the formulation. Based on the formulation being administered to a subject, the formulation is configured to perform to increase elasticity of lungs, reduce of inflammation within lungs, minimize buildup of fluid within the lungs, and facilitate removal of mucus from the lungs of the subject, reduce pneumonia thereby improving respiratory function of the lungs, and/or stop or reduce viral replication. Note that the formulation may be implementation in a gel type form or a dry type form. | 2021-12-23 |
20210393580 | PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19 - A composition that includes procyanidins for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including for use in treating symptomatic post-COVID-19 subjects recovering from COVID-19. | 2021-12-23 |
20210393581 | Composition for Preventing or Treating Obesity or Lipid-Related Metabolic Disorders - The present disclosure relates to a functional composition for the prevention, amelioration or treatment of obesity or lipid-related metabolic disorders, which comprises a steroid sulfatase inhibitor as an active ingredient. | 2021-12-23 |
20210393582 | SMALL ORGANIC MOLECULES FOR USE IN THE TREATMENT OF NEUROINFLAMMATORY DISORDERS - This invention provides small organic molecules useful as therapeutics of neurodegenerative diseases. Small organic molecules that act as inhibitors of bone morphogenetic proteins (BMPs) are useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis. | 2021-12-23 |
20210393583 | METHOD FOR THE TREATMENT OF PANCREATITIS - A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. | 2021-12-23 |
20210393584 | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS - Provided herein are amino acid compositions useful for increasing the translocation of the cystic fibrosis transmembrane conductance (CFTR) protein from the cytoplasm to the plasma membrane, particularly in epithelial cells. Methods for increasing the concentration of CFTR in the plasma membrane, increasing chloride ion transport, and increasing water transport are also provided. These compositions and methods are useful in treating cystic fibrosis in subjects bearing one or more mutations in the CFTR protein. Use of these compositions for the treatment of cystic fibrosis and in the preparation of a medicament for the treatment of cystic fibrosis are also encompassed herein. | 2021-12-23 |
20210393585 | METHOD FOR PREVENTING AND/OR TREATING A STRESS-INDUCED DISEASE - The present disclosure provides a method for preventing and/or treating a stress-induced disease in a subject in need of such treatment, comprising administering to said subject an effective amount of tanshinone IIA or a derivative of tanshinone IIA, or a pharmaceutically acceptable salt, solvate, hydrate, isotopologue, or prodrug of tanshinone IIA or a derivative of tanshinone IIA, and optionally a pharmaceutically acceptable carrier or excipient. | 2021-12-23 |
20210393586 | Compounds for Use in the Treatment of Bacterial Infections - The present invention relates to a compound which can be used in the treatment of infections with pathogenic bacteria, in particular pathogens mediating pathogenicity by quinolone dependent production of virulence factors, such as e.g. | 2021-12-23 |
20210393587 | ASENAPINE-CONTAINING ADHESIVE PATCH - An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62. | 2021-12-23 |
20210393588 | READY TO USE INTRAVENOUS INFUSION OF BRIVARACETAM OR SALT THEREOF - The present disclosure relates to the ready to use intravenous infusion of Brivaracetam or salt thereof. The ready to use intravenous infusion of Brivaracetam or salt thereof provides longer stability, which can be administered for longer period of time, with direct use without prior dilution, which saves time for dilution in case of emergency, with better ease of handling and which is efficacious; provide better patient compliance in the treatment of seizures. | 2021-12-23 |
20210393589 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA - The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor. | 2021-12-23 |
20210393590 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: | 2021-12-23 |
20210393591 | TREATMENTS FOR CHARCOT-MARIE-TOOTH DISEASE - Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease, comprising an inhibitor of a GCN2 pathway component. | 2021-12-23 |
20210393592 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY - The present invention relates to a pharmaceutical composition comprising cibenzoline, especially, S(−)-cibenzoline or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of hypertrophic cardiomyopathy, and a method for treatment of hypertrophic cardiomyopathy by using same. The treatment composition and method according to the present invention is used to treat a patient suffering from hypertrophic cardiomyopathy. In addition, the composition and method according to the present invention has excellent efficacy and safety, compared to conventional off-label standard of care (SOC). | 2021-12-23 |
20210393593 | USE OF HISTIDINE, GLYCINE AND OTHER AMINO ACIDS FOR PREVENTING INSULIN RESISTANCE AND/OR DIABETES - The invention relates to compositions and methods using a combination of at least one histidine or derivative thereof, at least one glycine or derivative thereof, and at least one additional agent selected from N-acetyl-cysteine, lysine, or arginine. An aspect of the invention is a method of promoting healthy fat metabolism and metabolic health in children at risk of developing insulin resistance and diabetes, promoting healthy lipolysis and use of fatty acid in metabolism, promoting healthy fat and adipocyte metabolism during puberty and adolescence, treating or preventing oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, or a condition associated with a reduced level of glutathione, by administering an effective amount of a combination of at least one glycine or derivative thereof, and lysine. | 2021-12-23 |
20210393594 | FORMULATIONS OF BENDAMUSTINE - Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C. | 2021-12-23 |
20210393595 | ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention provides a combination of a 5HT3-antagonist and/or a NK-1 antagonist with 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine and with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, zonisamide or a pharmaceutically acceptable salt or solvate thereof, or a statin or a pharmaceutically acceptable salt or solvate thereof, for use for treating a protein misfolding neurodegenerative disease such as Alzheimer's disease, Lewy body disease, Parkinson's disease, or Huntington's disease. | 2021-12-23 |
20210393596 | DRUG FOR TREATING TINNITUS - Compounds, pharmaceutical compositions, and methods for treating tinnitus in a subject in need thereof. The methods include administering a therapeutically effective amount of a compound having a structure represented by Formula I as described herein. The compounds and compositions are administered transdermally or orally, preferably via a sustained release mechanism. The compounds and compositions reduce at least one behavioral correlate of tinnitus and/or at least one neurophysiological correlate of tinnitus. The compounds and compositions reduce hyperactivity in the auditory system. | 2021-12-23 |
20210393597 | TARGETING THE TRANSCRIPTION FACTOR NF-KB WITH HARMINE - The present invention relates to compositions and methods for treating cancer with harmine. | 2021-12-23 |
20210393598 | UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALER - A composition comprising particulate umeclidinium or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof, and 1,1-difluoroethane. | 2021-12-23 |
20210393599 | MODULATORS OF THE INTEGRATED STRESS PATHWAY - Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions. | 2021-12-23 |
20210393600 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors - Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. | 2021-12-23 |
20210393601 | EZH1/2 DUAL INHIBITOR-CONTAINING PHARMACEUTICAL COMPOSITION TO BE USED AS A COMBINATION DRUG - An object of the present invention is to provide a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect. Provided is a combination drug having an EZH1/2 dual inhibitor in combination with another medical agent and exerting an excellent anticancer effect. | 2021-12-23 |
20210393602 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2021-12-23 |
20210393603 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2021-12-23 |
20210393604 | NOVEL BENZIMIDAZOLONE COMPOUND AND PHARMACEUTICAL USE THEREOF - The present invention relates to a medicament for treating or preventing a disease involving Nav 1.7, specifically such neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, comprising a compound of formula (I) wherein R | 2021-12-23 |
20210393605 | ALK2 INHIBITORS FOR THE TREATMENT OF ANEMIA - Provided herein are methods of treating anemia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an ALK2 inhibitor. | 2021-12-23 |
20210393606 | THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION - The present invention provides a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment caused by chronic stress, dementia with lewy bodies, progressive supranuclear palsy, frontotemporal dementia and the like) and the like), Lewy body disease (for example, cognitive impairment in Parkinson's disease, diffuse Lewy body disease, dementia with lewy bodies, movement disorder associated with Lewy body disease and the like) and the like, which contains a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. | 2021-12-23 |
20210393607 | Transdermal Patch Containing Fentanyl as Active Ingredient - Disclosed is a patch containing a plaster having fentanyl, an adhesive, a volatile hydrocarbon solvent (A), and a heteroatom-containing volatile organic solvent (B). | 2021-12-23 |
20210393608 | SUBSTITUTED INDOLE DIMER COMPOUNDS - Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G | 2021-12-23 |
20210393609 | METHOD FOR IMPROVING STABILITY OF LOW-CONCENTRATION ATROPINE OPHTHALMIC PREPARATION - The application provides a method for improving the stability of a low-concentration atropine ophthalmic preparation, characterized by controlling the content of the total impurity ≤0.25% and/or a single impurity content of ≤0.05%, as well as a method for preparing the ophthalmic preparation, an atropine ophthalmic preparation prepared therefrom and use thereof in the manufacture of a medicament for preventing and/or treating vision defects. | 2021-12-23 |